PomDoctor Ltd experiences significant decline amid market conditions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 Dec 25
Source: Coinmarketcap
PomDoctor Ltd's stock price fell by 87.34%, crossing below the 5-day SMA, reflecting a challenging trading environment.
The company's recent report highlighted a 16.2% net revenue growth in the first half of 2025, driven by a surge in its online pharmacy segment. However, the overall market sentiment remains weak, impacting investor confidence.
This decline raises concerns about the company's ability to sustain growth amid increasing competition and market volatility, suggesting that investors should closely monitor future performance and strategic initiatives.
Analyst Views on POM
About POM
PomDoctor Ltd is a holding company principally engaged in operating a online medical services platform for chronic diseases. The Company operates its businesses through two segments. The Internet Hospital segment mainly engaged in providing online follow-up consultations and online prescription renewal service to customers and also sells prescription to customers through the website and apps. The Pharmaceutical Supply Chain segment mainly engaged in pharmacy retail sales and wholesale. The Company mainly operates its businesses in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
